Appendix A

Claim Amendments

1. (Currently amended) Compounds A compound of formula I

in which

R1 is 1-4C-alkoxy,

A is 1-4C-alkylene,

- B represents 3H-imidazo[4,5-b]pyridin-2-yl, 3H-imidazo[4,5-b]pyridin-2-yl substituted by R2 and/or R3, 9H-purin-8-yl or 9H-purin-8-yl substituted by R4 and/or R5, where
- R2 halogen, hydroxyl, nitro, amino, 1-7C-alkvl, trifluoromethyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy, 1-4Calkoxycarbonyl, mono- or di-1-4C-alkylaminocarbonyl, monodi-1-4C-alkylaminosulfonyl, or 1-4Calkylcarbonylamino, 1-4C-alkylsulfonylamino, phenyl, phenyl substituted by R21 and/or R211, phenyl-1-4C-

alkyl, phenyl-1-4C-alkyl wherein the phenyl moiety is substituted by R22, phenyl-1-4C-alkoxy, pyridyl, pyridyl substituted by R23, pyridyl-1-4C-alkyl, pyridyl-1-4C-alkyl wherein the pyridyl moiety is substituted by R24, where

R21 is cyano, halogen, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylamino, 1-4C-alkoxycarbonyl, aminosulfonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C-alkylamino, trifluoromethyl, hydroxyl, phenylsulfonylamino or phenyl-1-4C-alkoxy,

R211 is halogen or 1-4C-alkoxy,

R22 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R23 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R24 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R3 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R4 is halogen, amino, 1-4C-alkyl, 1-4C-alkoxy or phenyl,

R5 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

(Currently amended) Compounds A compound of formula I according to claim 1 in which

R1 is 1-4C-alkoxy,

A is 1-4C-alkylene,

- B represents 3H-imidazo[4,5-b]pyridin-2-yl, 3H-imidazo[4,5-b]pyridin-2-yl substituted by R2 and/or R3, 9H-purin-8-yl or 9H-purin-8-yl substituted by R4 and/or R5, where
- R2 is chlorine, bromine, fluorine, hydroxyl, nitro, amino, 1-7C-alkyl, trifluoromethyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, 1-4C-alkylcarbonylamino, 1-4C-alkylsulfonylamino, phenyl, phenyl substituted by R21, phenyl-1-4C-alkyl, phenyl-1-4C-alkyl wherein the phenyl moiety is substituted by R22, phenyl-1-4C-alkoxy, pyridyl, pyridyl substituted by R23, pyridyl-1-4C-alkyl, pyridyl-1-4C-alkyl wherein the pyridyl moiety is substituted by R24, where

- R21 is cyano, chlorine, bromine, fluorine, carboxyl,

 1-4C-alkyl, 1-4C-alkoxy, aminocarbonyl, mono- or

 di-1-4C-alkylaminocarbonyl, 1-4Calkylcarbonylamino, 1-4C-alkoxycarbonyl,
 aminosulfonyl or mono- or di-1-4Calkylaminosulfonyl,
- R22 is chlorine, bromine, fluorine, 1-4C-alkyl or 1-4C-alkoxy,
- R23 is chlorine, bromine, fluorine, 1-4C-alkyl or 1-4C-alkoxy,
- R24 is chlorine, bromine, fluorine, 1-4C-alkyl or 1-4C-alkoxy,
- R3 is chlorine, bromine, fluorine, 1-4C-alkyl or 1-4C-alkoxy,
- R4 is chlorine, bromine, fluorine, 1-4C-alkyl, 1-4C-alkoxy or phenyl,
- R5 is chlorine, bromine, fluorine, 1-4C-alkyl or 1-4C-alkoxy,

3. (Currently amended) $\frac{A \ compound}{A \ compound}$ of formula I according to claim 1 in which

R1 is methoxy,

A is ethylene,

- B represents 3H-imidazo[4,5-b]pyridin-2-yl, 3H-imidazo[4,5-b]pyridin-2-yl substituted by R2 and/or R3, 9H-purin-8-yl or 9H-purin-8-yl substituted by R4 and/or R5, where
- R2 is halogen, hydroxyl, nitro, 1-7C-alkyl, trifluoromethyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy, 1-4Calkoxycarbonyl, phenyl, phenyl substituted by R21 and/or R211, phenyl-1-4C-alkyl, phenyl-1-4C-alkyl wherein the phenyl moiety is substituted by R22, phenyl-1-4C-alkoxy, pyridyl, pyridyl substituted by R23, pyridyl-1-4C-alkyl, pyridyl-1-4C-alkyl wherein the pyridyl moiety is substituted by R24, where
 - R21 is cyano, halogen, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-

alkylamino, trifluoromethyl, hydroxyl, phenylsulfonylamino or phenyl-1-4C-alkoxy,

R211 is halogen or 1-4C-alkoxy,

R22 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R23 is 1-4C-alkyl,

R24 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R3 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R4 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

R5 is halogen or 1-4C-alkyl,

the salts, the N-oxides and the salts of the N-oxides of these compounds or a hydrate, solvate, salt, hydrate of a salt, solvate of a salt, N-oxide or salt of an N-oxide thereof.

4. (Currently amended) Compounds A compound of formula I according to claim 1 in which

R1 is methoxy,

A is ethylene,

- B represents 3H-imidazo[4,5-b]pyridin-2-yl, 3H-imidazo[4,5-b]pyridin-2-yl substituted by R2 and/or R3, or 9H-purin-8-yl, where
- R2 is halogen, hydroxyl, nitro, 1-7C-alkyl, trifluoromethyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-

alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxy-1-4C-alkoxy, 1-4C-alkoxycarbonyl, phenyl, phenyl substituted by R21 and/or R211, phenyl-1-4C-alkyl, phenyl-1-4C-alkyl wherein the phenyl moiety is substituted by R22, phenyl-1-4C-alkoxy, pyridyl, pyridyl-1-4C-alkyl, pyridyl-1-4C-alkyl wherein the pyridyl moiety is substituted by R24, where

R21 is cyano, halogen, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylcarbonylamino, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-alkylamino, trifluoromethyl, hydroxyl, phenylsulfonylamino or phenyl-1-4C-alkoxy,

R211 is halogen or 1-4C-alkoxy,

R22 is halogen or 1-4C-alkyl,

R24 is 1-4C-alkoxy,

R3 is 1-4C-alkyl,

5. (Currently amended) $\frac{A}{A}$ compound of formula I according to claim 1 in which

R1 is methoxy,

A is ethylene,

imidazo[4,5-b]pyridine,

B represents 3H-imidazo[4,5-b]pyridin-2-yl, 7-methyl-3H-imidazo[4,5-b]pyridin-2-yl, 5,7-dimethyl-3H-imidazo[4,5-b]pyridin-2-yl, 5-methoxy-3H-imidazo[4,5-b]pyridin-2-yl, 6-bromo-3H-imidazo[4,5-b]pyridin-2-yl or 9H-purin-8-yl,

the salts, the N-oxides and the salts of the N-oxides of these compounds or a hydrate, solvate, salt, hydrate of a salt, solvate of a salt, N-oxide or salt of an N-oxide thereof.

6. (Currently amended) Compounds A compound according to claim 1 selected from the group consisting of 2-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine,

8-[2-(4-methoxypyridin-2-yl)ethyl]-9H-purine,

2-[2-(4-methoxypyridin-2-yl)ethyl]-7-methyl-3H-imidazo[4,5-b]pyridine,

2-[2-(4-methoxypyridin-2-yl)ethyl]-5,7-dimethyl-3H-

2-[2-(4-methoxypyridin-2-yl)ethyl]-5-methoxy-3Himidazo[4,5-b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-bromo-3H-imidazo[4,5b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-nitro-3H-imidazo[4,5b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-trifluoromethyl-3Himidazo[4,5-b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-phenyl-3H-imidazo[4,5b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-methyl-3H-imidazo[4,5b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(2-methylpropyl)-3Himidazo[4,5-b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-cyclohexylmethyl-3Himidazo[4,5-b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(2-phenylethyl)-3Himidazo[4,5-b]pyridine, 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(3,4-dichlorphenyl)-3H-imidazo[4,5-b]pyridine,

```
2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(4-bromphenyl)-3H-imidazo[4,5-b]pyridine,
```

2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(4-brombenzyl)-3H-imidazo[4,5-b]pyridine,

7-(2-methoxyethoxy)-2-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine,

2-[2-(4-methoxypyridin-2-yl)ethyl]-7-(2-phenylethoxy)-3H-imidazo[4,5-b]pyridine,

2-[2-(4-methoxypyridin-2-yl)ethyl]-7-(2,2,2-trifluoro-ethoxy)-3H-imidazo[4,5-b]pyridine,

7-hydroxy-2-[2-(4-methoxypyridin-2-yl)ethyl]-3Himidazo[4,5-b]pyridine,

2-[2-(4-methoxypyridin-2-yl)ethyl]-7-(2-p-tolylethyl)-3H-imidazo[4,5-b]pyridine,

2,7-bis-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine,

2-[2-(4-methoxypyridin-2-yl)ethyl]-7-(2-pyridin-yl-ethyl)-3H-imidazo[4,5-b]pyridine,

2-[2-(4-methoxypyridin-2-yl)ethyl]-6-p-tolyl-3H-imidazo[4,5-b]pyridine,

2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine,

```
2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(4-aminophenyl)-3H-
imidazo[4,5-b]pyridine,
2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(4-hydroxyphenyl)-3H-
imidazo[4,5-b]pyridine,
2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(4-N,N-
dimethylaminophenyl)-3H-imidazo[4,5-b]pyridine,
2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(4-
trifluormethylphenyl)-3H-imidazo[4,5-b]pyridine,
2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(3,4-dimethoxyphenyl)-
3H-imidazo[4,5-b]pyridine,
2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(4-benzyloxyphenyl)-
3H-imidazo[4,5-b]pyridine,
2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(4-benzyloxy-3-
fluorophenyl)-3H-imidazo[4,5-b]pyridine,
2-[2-(4-methoxypyridin-2-yl)ethyl]-6-(4-cyanophenyl)-3H-
imidazo[4,5-b]pyridine,
2-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-
b]pyridine-6-carboxylic acid methyl ester,
N-(4-\{2-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-
b]pyridine-6-yl}phenyl)-acetamide,
N-(4-\{2-[2-(4-methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-
b]pyridine-6-yl}phenyl)-benzenesulfonamide,
```

2-[2-(4-methoxy-1-oxy-pyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine,

- 7. (Currently amended) A method for treating a disease or disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound Compounds of formula I according to claim 1 or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt, solvate of a salt, N-oxide or salt of an N-oxide thereof for the treatment of diseases.
- 8. (Currently amended) Pharmaceutical compositions A pharmaceutical composition containing one or more compounds of formula I according to claim 1, or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt, solvate of a salt, N-oxide or salt of an N-oxide thereof, together with the usual pharmaceutical auxiliaries and/or excipients a pharmaceutically acceptable auxiliary and/or excipient.

9.-10. (Canceled)

- 11. (Currently amended) A method for treating <u>an</u> acute inflammatory <u>disease</u> diseases in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I according to claim 1 <u>or a pharmaceutically acceptable hydrate</u>, solvate, salt, hydrate of a salt, solvate of a salt, N-oxide or salt of an N-oxide thereof.
- 12. (Currently amended) A method for treating <u>a</u> chronic inflammatory <u>disease</u> diseases of <u>a</u> peripheral <u>organ</u> organs and the CNS and/or the central nervous system (CNS) in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt, solvate of a salt, N-oxide or salt of an N-oxide thereof.